(Q39017796)

8 September 2017

Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells (English)

1 reference

8 September 2017

1 reference

Lijun Mao

1

1 reference

8 September 2017

Chunhua Yang

2

1 reference

8 September 2017

Liantao Li

3

1 reference

8 September 2017

Lanzhou Nai

4

1 reference

8 September 2017

Li Fan

5

1 reference

8 September 2017

Junqi Wang

6

1 reference

8 September 2017

Wang Li

7

1 reference

8 September 2017

Rumin Wen

8

1 reference

8 September 2017

Jiacun Chen

9

1 reference

8 September 2017

Junnian Zheng

10

1 reference

8 September 2017

7 March 2014

1 reference

8 September 2017

1 reference

8 September 2017

35

1 reference

8 September 2017

5937-5944

1 reference

8 September 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-014-1787-2

8 September 2017

0 references

cites work

Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

PMN and anti-tumor immunity--the case of bladder cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

Evolution of oncolytic adenovirus for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

The death effector domain protein family: regulators of cellular homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

5-allyl-7-gen-difluoromethoxychrysin enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

microRNA response elements-regulated TRAIL expression shows specific survival-suppressing activity on bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

Mouse orthotopic models for bladder cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

TRAIL gene therapy: from preclinical development to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1787-2

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24604329

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Urothelial cancer cell response to combination therapy of gemcitabine and TRAIL.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24604329

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24604329

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13277-014-1787-2

1 reference

8 September 2017

1 reference